Poniard Pharmaceuticals Announces Upcoming Conference Participation

SOUTH SAN FRANCISCO, Calif., Aug. 27 /PRNewswire-FirstCall/ -- Poniard
Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on
oncology, today announced that Jerry McMahon, Ph.D., chairman and CEO, will
participate in three upcoming conferences in September during which he will
provide a corporate overview, including a discussion of the clinical
development program for picoplatin, the Company's lead product candidate.
-- The Thomas Weisel Partners Healthcare Conference on Wednesday,
September 3, at 4:25 p.m. Eastern Time at the Four Seasons Hotel in Boston
-- BioCentury's NewsMakers in the Biotech Industry Conference on Thursday,
September 4, at 2:30 p.m. Eastern Time at the Millennium Broadway Hotel in New
York
-- The 3rd Annual Citi Biotech Day on Monday, September 8, at 2:35 p.m.
Eastern Time at the Citi Center in New York
Live audio webcasts of Poniard's presentations at the Thomas Weisel
Partners Healthcare Conference and Citi Biotech Day will be available for 10
business days following each conference. Each webcast can be accessed on the
"Events" page of the "News & Events" section of the Company's website at
http://www.poniard.com.
About Poniard Pharmaceuticals
Poniard Pharmaceuticals, Inc. is a biopharmaceutical company focused on
the development and commercialization of innovative oncology products to
impact the lives of people with cancer. Picoplatin, the Company's lead
platform product candidate, is a new generation platinum therapy with an
improved safety profile relative to existing platinum-based cancer therapies.
Picoplatin is designed to overcome platinum resistance associated with
chemotherapy in solid tumors, and is being studied in multiple cancer
indications, combinations and formulations. Clinical trials of intravenous
picoplatin include a Phase 3 trial in small cell lung cancer and Phase 2
trials in metastatic colorectal and hormone-refractory prostate cancers, as
well as a clinical trial of oral picoplatin in solid tumors. Picoplatin has
not been approved by any regulatory authority for use in humans. For
additional information please visit http://www.poniard.com.
(C) 2008 Poniard Pharmaceuticals, Inc. All Rights Reserved.
Poniard and Poniard Pharmaceuticals are trademarks of Poniard
Pharmaceuticals, Inc.
SOURCE Poniard Pharmaceuticals, Inc.

Brendan Doherty, Corporate Communications of Poniard Pharmaceuticals,
+1-650-745-4425, bdoherty@poniard.com